Report Overview

The global cell expansion market was pegged at US$ 17.25 billion in 2021 and is expected to witness a CAGR of 15% during the forecast period.

Market Fundamentals 

Cell expansion refers to the enormously artificial generation of daughter cells from a single cell in order to facilitate medical research. For cells to expand, new cell wall material must be produced, and the wall must be gradually loosened to allow for stretching and area growth. For example, drug development, drug screening, and cell expansion are all employed in life science research and development. To accommodate cell expansion and allow it to expand and develop in the region, fresh cell wall material must be incorporated, and the wall must be gradually loosened. Important elements in this process are cell-wall-associated proteins from the so-called expansion family. Cell culturing in bioreactors is a controlled procedure that calls for controlled environmental factors, including regulated gas content for the cells' extension, monitored flow rates, ambient temperature, pH, agitation of the cells, and controlled flow of cells.

[789324]

Market Dynamics

The prevalence of chronic diseases is rising, and this trend is being accompanied by a rise in government support for and private sector investment in R&D programmes. Antibiotics, medicines, treatments, and vaccines are all made with it. Comprehensive research is necessary to develop new treatment options due to the rising prevalence of diseases like cancer and diabetes. Additionally, the typical move toward Single-Use Systems (SUS) offers numerous production benefits in the production of Cell Therapy Products (CTP). Cross-contamination and culture infection brought on by insufficient sterilisation are dismissed by SUS.

Market Ecosystem 

The global cell expansion market has been analysed into five perspectives by product, cell type, application, end user and region.

Cell Expansion Market by Product

[232721]

Based on product, the global cell expansion market has been segmented into consumables, culture flasks and accessories, instruments and others. The segment for consumables is anticipated to experience the highest CAGR during the forecast period. The segment for instruments is divided into cell expansion supporting equipment, bioreactors, and automated cell expansion systems, while the segment for consumables is further divided into reagents, medium, sera, and disposables. The increased manufacturing of vaccines and other biologics in the biopharmaceutical and biotechnology sectors is one of the causes that might be linked to the segment's rise.

Cell Expansion Market by Cell Type

Based on cell type, the global cell expansion market has been segmented into mammalian, microbial cell and others. The segment for mammalian cells is anticipated to experience the highest CAGR during the projection period. The exponential rise of research in this field and the enormous success of regenerative medicine are variables that can be linked to the segment's growth. Additionally, throughout the projected period, the segment growth is driven by the adoption of automated, robotic, and closed production systems in the manufacturing of clinical-grade mesenchymal stem cells.

Cell Expansion Market by Application

Based on application, the global cell expansion market has been segmented into biopharmaceuticals, tissue culture & engineering, vaccine production, drug development, gene therapy, cancer research, stem cell and regenerative medicine and others. For the projected period, the segment for regenerative medicine and stem cell research is anticipated to have the greatest CAGR. The increased financing for stem cell and regenerative medicine research is one of the variables that might be linked to the segment's rise.

Cell Expansion Market by End User

Based on end user, the global cell expansion market has been segmented into biopharmaceutical & biotechnology companies, research institutes, cell banks and others. The segment of research institutes is anticipated to see the highest CAGR during the forecast period. Organizations in the pharmaceutical and biopharmaceutical industries are also making acquisitions to diversify their product offerings.

Cell Expansion Market by Region

Based on region, the global cell expansion market has been segmented into North America, Europe, Asia Pacific, and Rest of the World. The North America dominated the global cell expansion market during forecast period. The increased emphasis on biopharmaceutical R&D, massive medication production, and rise in cancer prevalence are the main drivers of market growth in this area. The industry is also growing as a result of increased efforts made by numerous local pharmaceutical and biotechnology companies to create and promote their cellular medicines. For instance, in July 2019 an Indian business called Stempeutics Research Pvt. Ltd. struck a partnership agreement with Kemwell Biopharma for the commercialization of their Stempeucel stem cell-based product. These agreements should increase small- and mid-sized businesses' product sales.

Competitive Landscape 

Some of the prominent players in the global cell expansion market include, Beckman Coulter, Inc, Thermo Fisher Scientific, Inc., Cell Signaling Technology, Inc., Becton, Dickinson and Company, Terumo BCT, Inc., Takara Bio, Inc., Corning, Inc., Stemcell Technologies, Inc., GE Healthcare, Merck KGaA (Sigma-Aldrich Co. LLC), Lonza, Miltenyi Biotec, Octane Biotech, Inc., Corning Incorporated, Eppendorf AG, and Lonza Group.

Strategic development 

• In March 2020, Applikon Biotechnology B.V. (Applikon), a Dutch company, recently announced a cooperation with Sotelab of Brazil, one of Latin America's top suppliers and distributors of laboratory and life sciences equipment. The collaboration between Applikon and Rio de Janeiro-based Sotelab Sociedade Técnica de Laboratório Ltda (Sotelab) considerably expands Applikon's advanced cultivation systems' market position in South America.
• In March 2020, the acquisition of the biopharma division of General Electric Co. by Danaher Corp. was finalised for USD 21.4 billion. The startup will be known as Cytiva and will operate independently under Danaher's bio sciences division.

Frequently Asked Questions About This Report